Haemonetics Corporation has released its financial results for fiscal year 2025, reporting a 4.0% increase in net revenues compared to fiscal 2024. This growth was mainly driven by the Hospital business, which saw revenue increase by 23.7%, primarily due to recent acquisitions and growth in Interventional Technologies and Blood Management Technologies. In contrast, Blood Center revenue declined by 7.8%, largely due to a decrease in the Whole Blood business following its divestiture. Net income for fiscal 2025 was reported at $167.7 million, marking a 42.6% increase from the previous year. This improvement resulted in a net income per share of $3.33, up from $2.32 in fiscal 2024. The company attributed this increase to operating leverage, the remeasurement of contingent consideration, and gains from the sale of a manufacturing facility, despite incurring transaction and integration costs from recent acquisitions. Provision for income taxes increased to $44.4 million, constituting 20.9% of pre-tax income, compared to $34.3 million or 22.6% the previous year. The results reflect the company's strategic acquisitions and operational adjustments, contributing to the overall financial performance.